SG11201809497RA - Processes for preparing phosphorodiamidate morpholino oligomers - Google Patents

Processes for preparing phosphorodiamidate morpholino oligomers

Info

Publication number
SG11201809497RA
SG11201809497RA SG11201809497RA SG11201809497RA SG11201809497RA SG 11201809497R A SG11201809497R A SG 11201809497RA SG 11201809497R A SG11201809497R A SG 11201809497RA SG 11201809497R A SG11201809497R A SG 11201809497RA SG 11201809497R A SG11201809497R A SG 11201809497RA
Authority
SG
Singapore
Prior art keywords
street
international
cambridge
oligomer
processes
Prior art date
Application number
SG11201809497RA
Inventor
Bao Cai
Mitchell Martini
Katie Thomas
Ross Shimabuku
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of SG11201809497RA publication Critical patent/SG11201809497RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 30 November 2017 (30.11.2017) °mint H IDIIIDIDIIl Elan EH 011 (10) International Publication Number WO 2017/205880 Al WIPO I PCT (51) International Patent Classification: A61K 31/496 (2006.01) C07D 265/30 (2006.01) A61K 31/5377 (2006.01) (21) International Application Number: PCT/US2017/040318 (22) International Filing Date: 30 June 2017 (30.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/341,049 24 May 2016 (24.05.2016) US 62/340,953 24 May 2016 (24.05.2016) US 62/357,134 30 June 2016 (30.06.2016) US 62/357,166 30 June 2016 (30.06.2016) US 62/508,256 18 May 2017 (18.05.2017) US (71) Applicant: SAREPTA THERAPEUTICS, INC. [US/US]; 215 First Street, Cambridge, MA 02139 (US). (72) Inventors: CAI, Bao; c/o Sarepta Therapeutics, Inc., 215 First Street, Cambridge, MA 02142 (US). MARTINI, Mitchell; c/o Sarepta Therapeutics, Inc., 215 First Street, Cambridge, MA 02142 (US). THOMAS, Katie; c/o Sarep- ta Therapeutics, Inc., 215 First Street, Cambridge, MA 02142 (US). SHIMABUKU, Ross; c/o Sarepta Therapeu- tics, Inc., 215 First Street, Cambridge, MA 02142 (US). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with information concerning request for restoration of the right of priority in respect of one or more priority claims (Rules 26bis.3 and 48.2(b)(vii)) (74) Agent: TRINQUE, Brian, C. et al.; Lathrop & Gage, LLP, 28 State Street, Boston, MA 02109 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 1-1 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, O MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, pp TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). O N (54) Title: PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS 0 (57) : Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described \" herein may be advantageous to scaling up oligomer synthesis while maintaining overall yield and purity of a synthesized oligomer.
SG11201809497RA 2016-05-24 2017-06-30 Processes for preparing phosphorodiamidate morpholino oligomers SG11201809497RA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662340953P 2016-05-24 2016-05-24
US201662341049P 2016-05-24 2016-05-24
US201662357166P 2016-06-30 2016-06-30
US201662357134P 2016-06-30 2016-06-30
US201762508256P 2017-05-18 2017-05-18
PCT/US2017/040318 WO2017205880A1 (en) 2016-05-24 2017-06-30 Processes for preparing phosphorodiamidate morpholino oligomers

Publications (1)

Publication Number Publication Date
SG11201809497RA true SG11201809497RA (en) 2018-12-28

Family

ID=60412589

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201809497RA SG11201809497RA (en) 2016-05-24 2017-06-30 Processes for preparing phosphorodiamidate morpholino oligomers
SG10202101836TA SG10202101836TA (en) 2016-05-24 2017-06-30 Processes for preparing phosphorodiamidate morpholino oligomers

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202101836TA SG10202101836TA (en) 2016-05-24 2017-06-30 Processes for preparing phosphorodiamidate morpholino oligomers

Country Status (12)

Country Link
US (1) US20230045831A1 (en)
EP (1) EP3463363A4 (en)
AU (1) AU2017270975B2 (en)
BR (1) BR112018074340A2 (en)
CA (1) CA3024456A1 (en)
CO (1) CO2018013834A2 (en)
IL (1) IL263044B1 (en)
MA (1) MA45183A (en)
MX (1) MX2018014123A (en)
SA (1) SA518400467B1 (en)
SG (2) SG11201809497RA (en)
WO (1) WO2017205880A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (en) 2010-09-01 2016-07-11 日本新藥股份有限公司 Antisense nucleic acid
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
CN109563114B (en) 2016-05-24 2022-08-12 萨勒普塔医疗公司 Process for preparing oligomers
BR112018074270B1 (en) 2016-05-24 2021-02-02 Sarepta Therapeutics, Inc process for preparing oligomeric compounds as well as said compounds
MA45362A (en) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc PROCESSES FOR THE PREPARATION OF MORPHOLINO OLIGOMERS OF PHOSPHORODIAMIDATE
EP3630789A4 (en) 2017-06-02 2021-06-16 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
US11603532B2 (en) 2017-06-02 2023-03-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
WO2021025899A1 (en) 2019-08-02 2021-02-11 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer pharmaceutical compositions
AU2021277407A1 (en) * 2020-05-22 2022-11-17 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3650349T2 (en) 1985-03-15 1995-12-14 Antivirals Inc IMMUNOTEST FOR POLYNUCLEOTID AND METHOD.
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
WO1990002749A1 (en) 1988-09-01 1990-03-22 Forskningscenter Risø Peptide synthesis method and solid support for use in the method
US7759513B2 (en) * 2003-02-21 2010-07-20 Nigu Chemie Gmbh Photolabile protective groups for improved processes to prepare oligonucleotide arrays
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US9371348B2 (en) * 2006-11-27 2016-06-21 The Trustees Of The University Of Pennsylvania Photocleavable oligonucleotide and uses thereof
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
CA2884340C (en) 2007-11-15 2017-07-25 Sarepta Therapeutics, Inc. Method of synthesis of morpholino oligomers
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
KR101981705B1 (en) * 2010-05-28 2019-05-24 사렙타 쎄러퓨틱스, 인코퍼레이티드 Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
CN103154009B (en) 2010-09-30 2015-06-10 日本新药株式会社 Morpholino nucleic acid derivative
BR112014004174A2 (en) * 2011-08-23 2017-03-28 Hong Kong Polytechnic Univ ion labels for oligoribonucleotide synthesis
CN104039739A (en) * 2011-11-18 2014-09-10 萨勒普塔医疗公司 Functionally-modified oligonucleotides and subunits thereof
CA2857664A1 (en) 2011-11-30 2013-06-06 Sarepta Therapeutics, Inc. Antisense oligonucleotides targeting within the smn2 pre-mrna for use ininduced exon inclusion in spinal muscle atrophy
EP3287531B1 (en) * 2012-02-28 2019-06-19 Agilent Technologies, Inc. Method for attaching a counter sequence to a nucleic acid sample
EP2970964B8 (en) 2013-03-14 2019-03-06 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy

Also Published As

Publication number Publication date
MX2018014123A (en) 2019-04-29
MA45183A (en) 2019-04-10
IL263044B1 (en) 2024-02-01
EP3463363A4 (en) 2020-02-19
CA3024456A1 (en) 2017-11-30
BR112018074340A2 (en) 2019-03-06
WO2017205880A1 (en) 2017-11-30
AU2017270975B2 (en) 2021-04-15
SG10202101836TA (en) 2021-03-30
US20230045831A1 (en) 2023-02-16
SA518400467B1 (en) 2023-03-12
IL263044A (en) 2018-12-31
CO2018013834A2 (en) 2019-01-18
AU2017270975A1 (en) 2019-01-17
EP3463363A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201909949XA (en) Targeted immunotolerance
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201804934PA (en) Novel Compounds
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201804443UA (en) Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201909011PA (en) Niraparib compositions
SG11201408261UA (en) Syringe
SG11201408821SA (en) Selective pi3k delta inhibitors
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201404836QA (en) Long-acting coagulation factors and methods of producing same
SG11201804774YA (en) Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
SG11201810143PA (en) Exon skipping oligomers for muscular dystrophy
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201407184PA (en) Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals
SG11201909807TA (en) Methods of manufacturing of niraparib